Journal
LEUKEMIA RESEARCH
Volume 37, Issue 7, Pages 795-801Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2013.03.001
Keywords
Acute promyelocytic leukemia; All-trans retinoic acid; Late relapse
Categories
Funding
- Public Health Service Grant [CA21115, CA23318, CA66636, CA17145, CA14958, CA77658, CA32102, CA 37027, CA12213]
- National Cancer Institute, National Institutes of Health
- Department of Health and Human Services
- [CA021115]
- [CA114737]
- [CA56771]
Ask authors/readers for more resources
We report a long-term follow-up (median 11.8 years) of the First North American Intergroup Study. 379 patients were randomized to induction with ATRA or to chemotherapy. All complete responders (CR) received consolidation chemotherapy, then randomized to 1 year ATRA or observation. 245 patients received ATRA sometime during the study: 195 (80%) achieved a CR. Nine (4.6%) relapsed late (>3 years from CR), the last occurred after 4.6 years; 7 of them were still alive after 5.5-15 years. In APL patients, late relapses are uncommon, and those who sustain CR >5 years can be considered cured. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available